5069 POSTER Phase II Study Assessing Lapatinib Added to Letrozole in Patients With Progressive Disease Under Aromatase Inhibitor in Metastatic Breast Cancer – Study BES 06

European Journal of Cancer ◽

10.1016/s0959-8049(11)71511-8 ◽

2011 ◽

Vol 47 ◽

pp. S350-S351

Author(s):

C. Villanueva ◽

L. Chaigneau ◽

G. Romieu ◽

J. Salvat ◽

T. N'Guyen ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Progressive Disease ◽

Phase Ii Study ◽

Metastatic Breast ◽

Cancer Study ◽

Breast Cancer Study

Download Full-text

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06

Targeted Oncology ◽

10.1007/s11523-013-0279-4 ◽

2013 ◽

Vol 8 (2) ◽

pp. 137-143 ◽

Cited By ~ 5

Author(s):

C. Villanueva ◽

G. Romieu ◽

J. Salvat ◽

L. Chaigneau ◽

Y. Merrouche ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Progressive Disease ◽

Phase Ii Study ◽

Metastatic Breast ◽

Cancer Study ◽

Breast Cancer Study

Download Full-text

A phase II study of gemcitabine plus capecitabine (GC) in heavily pre-treated metastatic breast cancer patients. The Swedish GC Breast Cancer Study Group

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70736-5 ◽

2008 ◽

Vol 6 (7) ◽

pp. 175-176

Author(s):

A. Malmstrom ◽

J. Hansen ◽

L. Malmberg ◽

L. Carlsson ◽

J.H. Svensson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Study Group ◽

Breast Cancer Patients ◽

Cancer Study Group ◽

Breast Cancer Study

Download Full-text

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

10.1158/1538-7445.sabcs14-s2-02 ◽

2015 ◽

Cited By ~ 28

Author(s):

Ian Krop ◽

Stephen Johnston ◽

Ingrid A Mayer ◽

Maura Dickler ◽

Vinod Ganju ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pi3k Inhibitor

Download Full-text

Phase II study of the eortc breast group with vorozole (R 83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC) — preliminary results

European Journal of Cancer ◽

10.1016/0959-8049(93)91079-z ◽

1993 ◽

Vol 29 ◽

pp. S86 ◽

Cited By ~ 1

Author(s):

R. Paridaens ◽

M. Piccart ◽

M. Nooy ◽

J.G.M. Klijn ◽

R.D. Rubens ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Preliminary Results ◽

Breast Group

Download Full-text

A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps128 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS128-TPS128

Author(s):

D. A. Yardley ◽

R. Ismail-Khan ◽

J. F. Eakle ◽

K. Miller ◽

D. Paul ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Double Blind ◽

Deacetylase Inhibitor

Download Full-text

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

Her2 Positive

Download Full-text

Randomised Phase II Study of Palbociclib Plus Exemestane with GnRH Agonist Versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3414442 ◽

2019 ◽

Author(s):

Yeon Hee Park ◽

Tae-Yong Kim ◽

Gun Min Kim ◽

Kyung Hae Jung ◽

Seok Yun Kang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Gnrh Agonist ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Premenopausal Women ◽

Hormone Receptor Positive

Download Full-text

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2018-0243 ◽

2018 ◽

Vol 24 (6) ◽

pp. 743 ◽

Cited By ~ 1

Author(s):

Elisabetta Pietri ◽

Ilaria Massa ◽

Sara Bravaccini ◽

Sara Ravaioli ◽

Maria Maddalena Tumedei ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast

Download Full-text

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-005-0675-y ◽

2005 ◽

Vol 131 (9) ◽

pp. 568-574 ◽

Cited By ~ 8

Author(s):

Peter Schmid ◽

Volker Heilmann ◽

Carsten-Oliver Schulz ◽

Annette Dieing ◽

Silvia Lehenbauer-Dehm ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Prolonged Infusion

Download Full-text